Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Synthesis and biological properties are reported for some analogs of
oxytocin
with replacements of the isoleucine residue in position 3, i.e., (3-proline)
oxytocin
and(3-D-alanine)
oxytocin
, and the glutamine residue in position 4, i.e., (4-D-alanine)-
oxytocin
and (4-D-leucin)
oxytocin
. (3-Proline)
oxytocin
exhibited smaller than0.02 U/MG oxytocic activity, 0.005 plus or minus smaller than 0.001 U/mg rat pressor activity and 0.003 plus or minus 0.0001 U/mg antidiuretic activity. (3-D-Alanine)
oxytocin
had no agonistic activity in the bioassays tested except for the rat antidiuretic assay (smaller than 0.0005 U/mg). The 4-D-alanine analog showed 0.05 plus or minus 0.003 U/mg oxytocic activity, 0.07 plus or minus 0.01 U/mg avian vasodepressor activity, and smaller than 0.001 U/mg rat antidiuretic activity. (4-
D-Leucine
)
oxytocin
possessed 0.001 plus or minus U/mg rat pressor activity, and showed slight inhibitory properties in the oxytocic and avian vasodepressor assays, inhibiting the
oxytocin
response in the latter assay by about 60% at a girnibe-to-analog ratio of 1:5000. The activity profiles of the analogs are compared to that of
oxytocin
and are discussed on the basis of the proposed solution conformation of
oxytocin
.
...
PMID:Oxytocin analogs with substitutions in postions 3 and 4. 114 Aug 89